Cases & Deals

  • Home
  • Practices
  • Atara and leading cancer center develop patent portfolios for antigen-specific T cell therapies

Share

Atara and leading cancer center develop patent portfolios for antigen-specific T cell therapies

October 2024

Client(s) Atara Biotherapeutics, Inc.

Jones Day represents Atara Biotherapeutics, Inc. and a leading cancer center in the development of patent portfolios relating to antigen-specific T cell therapies, including EBVALLO™ (tabelecleucel).

Contacts

Before sending, please note:

Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice.